Analyze Diet
Veterinary journal (London, England : 1997)2008; 182(3); 384-391; doi: 10.1016/j.tvjl.2008.08.021

Clenbuterol and the horse revisited.

Abstract: Clenbuterol is a beta(2)-agonist and potent selective bronchodilator that is used to treat bronchospasm in the horse. The drug is normally administered to horses orally as a syrup formulation. Once absorbed into the systemic circulation, clenbuterol has the potential to cause many side effects, including a repartitioning effect and major alterations in cardiac and skeletal muscle function. Recent studies have also reported that clenbuterol can affect bone and the immune, endocrine and reproductive systems. A great deal of information has been published on the beneficial effects of short term therapeutic doses of clenbuterol on the equine respiratory system, although there is limited information about chronic administration, particularly since this has been associated with adverse physiological effects on other systems. This review summarizes the relevant understanding of clenbuterol for clinicians and horse owners who may administer this drug to pleasure and performance horses.
Publication Date: 2008-10-16 PubMed ID: 18926742DOI: 10.1016/j.tvjl.2008.08.021Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research is about Clenbuterol, a bronchodilator mostly used for treating bronchospasm in horses. The potential side effects of the drug when absorbed into the system – including major alterations in muscles and effects on bone, immune, endocrine and reproductive systems – are analyzed, with a special focus on the implications of its chronic administration.

Overview of Clenbuterol

  • Clenbuterol is a beta(2)-agonist and a bronchodilator that is frequently used to treat horses suffering from bronchospasm. This medication, normally administered as a syrup, helps to open up the airways, thereby facilitating better breathing.
  • Despite its beneficial effects, Clenbuterol can potentially cause several side effects once it is absorbed into the systemic circulation. The side effects are categorized into those affecting redistribution and those influencing the functioning of cardiac and skeletal muscles.

Impact on Other Physiological Systems

  • Recent studies have brought to light that Clenbuterol can impact various physiological systems such as bone, immune, endocrine, and reproductive systems. A multitude of positive effects of therapeutic doses of this drug on a horse’s respiratory system have been well-documented.
  • However, there is limited information available regarding the implications of chronic administration of Clenbuterol, even though it has been linked to adverse physiological effects on multiple systems.

Relevance for Clinicians and Horse Owners

  • This review aims to summarize the relevant knowledge regarding Clenbuterol for clinicians and horse owners who may have to administer this drug to pleasure and performance horses.
  • Therefore, this research holds importance in providing valuable insight that could improve the drug’s utilization in veterinary medicine, particularly in the care and management of horses. Hence, it will contribute to making more informed decisions on the administration and potential dangers of chronic use of Clenbuterol.

Cite This Article

APA
Kearns CF, McKeever KH. (2008). Clenbuterol and the horse revisited. Vet J, 182(3), 384-391. https://doi.org/10.1016/j.tvjl.2008.08.021

Publication

ISSN: 1532-2971
NlmUniqueID: 9706281
Country: England
Language: English
Volume: 182
Issue: 3
Pages: 384-391

Researcher Affiliations

Kearns, Charles F
  • Equine Science Center, Department of Animal Science, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
McKeever, Kenneth H

    MeSH Terms

    • Adrenergic beta-Agonists / adverse effects
    • Adrenergic beta-Agonists / therapeutic use
    • Animals
    • Bronchial Diseases / drug therapy
    • Bronchial Diseases / veterinary
    • Clenbuterol / adverse effects
    • Clenbuterol / therapeutic use
    • Dose-Response Relationship, Drug
    • Heart Diseases / chemically induced
    • Heart Diseases / veterinary
    • Horse Diseases / chemically induced
    • Horse Diseases / drug therapy
    • Horses
    • Muscle, Skeletal / drug effects
    • Oxygen Consumption / drug effects
    • Physical Conditioning, Animal / physiology

    Citations

    This article has been cited 5 times.
    1. Witkowska-Piłaszewicz O, Pingwara R, Szczepaniak J, Winnicka A. The Effect of the Clenbuterol-β2-Adrenergic Receptor Agonist on the Peripheral Blood Mononuclear Cells Proliferation, Phenotype, Functions, and Reactive Oxygen Species Production in Race Horses In Vitro. Cells 2021 Apr 17;10(4).
      doi: 10.3390/cells10040936pubmed: 33920705google scholar: lookup
    2. Martin EM, Messenger KM, Sheats MK, Jones SL. Misoprostol Inhibits Lipopolysaccharide-Induced Pro-inflammatory Cytokine Production by Equine Leukocytes. Front Vet Sci 2017;4:160.
      doi: 10.3389/fvets.2017.00160pubmed: 29034249google scholar: lookup
    3. Hostrup M, Moesgaard L, Fischer M, Wickham KA, Pleshardt M, Andersen AB, Bejder J, Thomassen M, Nielsen JJ, Dehnes Y, Bangsbo J, Nordsborg NB, Jessen S. Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle β(2)-adrenergic signalling. J Physiol 2025 Oct;603(19):5529-5545.
      doi: 10.1113/JP289023pubmed: 40946331google scholar: lookup
    4. Kataveni S, Gourishetty RP, Mundada SM, Avvaru MP, Kollipara VS, Gottimukkala SP. Clenbuterol Abuse in Bodybuilding and Athletics: Unsupervised Use, Psychological Motivations, and Health Consequences. Cureus 2025 May;17(5):e84904.
      doi: 10.7759/cureus.84904pubmed: 40575216google scholar: lookup
    5. Baker JG, Shaw DE. Asthma and COPD: A Focus on β-Agonists - Past, Present and Future. Handb Exp Pharmacol 2024;285:369-451.
      doi: 10.1007/164_2023_679pubmed: 37709918google scholar: lookup